argenx SE (ARGX) said that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Vyvgart (efgartigimod alfa) for intravenous (IV) use in adults with primary immune thrombocytopenia (ITP).
The approval of VYVGART was based on results from the global Phase 3 ADVANCE-IV trial. The trial successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.
For More Such Health News, visit rttnews.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.